gptkbp:instance_of
|
gptkb:Antihero
|
gptkbp:approves
|
gptkb:1993
gptkb:FDA
|
gptkbp:available_in
|
liquid form
orally disintegrating tablet
chewable form
|
gptkbp:available_on
|
gptkb:pharmaceuticals
|
gptkbp:average_temperature
|
room temperature
|
gptkbp:clinical_trial
|
Phase IV
Phase III
|
gptkbp:clinical_use
|
treatment of chronic urticaria
treatment of allergic conjunctivitis
treatment of skin allergies
treatment of allergic rhinitis
treatment of hay fever
|
gptkbp:color
|
gptkb:white
|
gptkbp:contraindication
|
lactation
pregnancy category B
hypersensitivity to loratadine
|
gptkbp:dosage_form
|
10 mg once daily
10 mg tablet
10 mg orally disintegrating tablet
5 mg chewable tablet
5 mg/5 m L syrup
|
gptkbp:excretion
|
urine
feces
|
gptkbp:form
|
gptkb:tablet
gptkb:Sugar
|
https://www.w3.org/2000/01/rdf-schema#label
|
Clarityn
|
gptkbp:ingredients
|
gptkb:loratadine
|
gptkbp:interacts_with
|
gptkb:beer
CYP2 D6 inhibitors
CYP3 A4 inhibitors
|
gptkbp:invention
|
gptkb:2011
|
gptkbp:lifespan
|
8 hours
|
gptkbp:manufacturer
|
gptkb:Bristol-Myers_Squibb
|
gptkbp:marketed_as
|
gptkb:Clarinex
gptkb:Claritin
gptkb:Alavert
|
gptkbp:mechanism_of_action
|
H1 receptor antagonist
|
gptkbp:metabolism
|
liver
|
gptkbp:packaging
|
gptkb:bottle
blister pack
|
gptkbp:previous_name
|
gptkb:loratadine
|
gptkbp:related_to
|
hay fever
perennial allergic rhinitis
seasonal allergic rhinitis
|
gptkbp:side_effect
|
fatigue
headache
nausea
rash
drowsiness
dry mouth
anaphylaxis
thrombocytopenia
palpitations
elevated liver enzymes
|
gptkbp:taste
|
gptkb:sweet
|
gptkbp:used_for
|
allergy relief
|
gptkbp:bfsParent
|
gptkb:Schering_AG
|
gptkbp:bfsLayer
|
6
|